Mobia Medical (NASDAQ:MOBI) CFO Nelson Bunker Curnes Purchases 5,000 Shares

Mobia Medical, Inc. (NASDAQ:MOBI) CFO Nelson Bunker Curnes bought 5,000 shares of the firm’s stock in a transaction dated Tuesday, June 9th. The stock was bought at an average cost of $12.79 per share, with a total value of $63,950.00. Following the transaction, the chief financial officer directly owned 366,997 shares of the company’s stock, valued at approximately $4,693,891.63. This trade represents a 1.38% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.

Mobia Medical Price Performance

Shares of NASDAQ MOBI traded down $0.40 on Thursday, hitting $12.32. The company had a trading volume of 165,707 shares, compared to its average volume of 163,509. Mobia Medical, Inc. has a 12-month low of $10.19 and a 12-month high of $14.77. The company has a market capitalization of $409.63 million, a price-to-earnings ratio of 66.00 and a beta of 2.84.

Mobia Medical (NASDAQ:MOBI) last issued its earnings results on Thursday, June 4th. The company reported $999.00 earnings per share for the quarter. The company had revenue of $12.07 million during the quarter.

Analyst Ratings Changes

A number of research firms have weighed in on MOBI. Wolfe Research initiated coverage on shares of Mobia Medical in a research report on Tuesday, June 2nd. They issued an “outperform” rating for the company. BTIG Research assumed coverage on shares of Mobia Medical in a research note on Tuesday, June 2nd. They set a “buy” rating and a $19.00 price objective on the stock. Bank of America assumed coverage on Mobia Medical in a research note on Tuesday, June 2nd. They set a “buy” rating and a $16.00 price objective on the stock. The Goldman Sachs Group assumed coverage on Mobia Medical in a research note on Tuesday, June 2nd. They set a “buy” rating and a $31.00 price objective on the stock. Finally, Wall Street Zen cut Mobia Medical from a “hold” rating to a “sell” rating in a research note on Saturday, June 6th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $20.25.